OncXerna Theraputics, Inc.
3 clinical trials · Sponsor
◉ Watch OncXerna Theraputics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer (NCT05043402) | OncXerna Theraputics, Inc. | 2022-11-30 |
| A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors (NCT05453825) | OncXerna Theraputics, Inc. | 2022-08-05 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients (NCT04099641) | OncXerna Theraputics, Inc. | 2019-09-11 |
Track OncXerna Theraputics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.